Phase 1a data in 16 patients with recurrent glioblastoma established a recommended dose for expansion of LP-184 for a planned phase 1b/2a combination trial.
|Videos|November 9, 2012
An 80-Year-Old Man Presents With Abdominal Pain and Tarry Stools
In this Stump the Professor video, two fellows test Dr. Marshall's diagnostic skills with a unique case study involving an 80-year-old patient who presents with abdominal pain, bilateral edema, weight loss, and dark, tarry stools.
Advertisement
In this video, two fellows-Brandon Smaglo, MD, and Sameh E. Mikhail, MD-from the Lombardi Cancer Center at Georgetown University attempt to stump John L. Marshall, MD, director of the Ruesch Center for the Cure of Gastrointestinal Cancers, with a unique case study involving an 80-year-old patient who presents with abdominal pain, bilateral edema, weight loss, and dark and tarry stools.
Advertisement
Related to this article
The FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.
The FDA approved pimicotinib for TGCT based on phase 3 MANEUVER data showing durable responses and improved pain, stiffness, and function.
Real-world data showed a 68% 12-month high-grade recurrence-free survival rate with hyperthermic mitomycin C in patients with BCG-unresponsive NMIBC.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
The FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026
5